MyChart is not for medical emergencies. If you have a medical emergency, call 911.
If you need help with MyChart, call us at 1-844-442-4278.
By connecting highly effective cancer immunotherapy drugs such as anti-CTLA4 (ipilimumab) and anti-PD-L1 (atezolizumab) to peptides that bind to tissues in and around tumors, a research team based at the University of Chicago found a way to improve the drugs’ impact while limiting treatment-related side effects.
Rita Nanda, MD, presents results from the I-SPY 2 trial at the ASCO annual meeting showing that adding the checkpoint blocker pembrolizumab (KeytrudaTM) to standard therapy dramatically improved response rates for patients with invasive triple-negative breast cancer.